Too Few Early Breast CA Patients Given Formal Genetic Counseling
WEDNESDAY, March 14, 2018 -- Many women with early-stage breast cancer with indications for formal genetic risk evaluation do not receive formal counseling, according to a study published online March 12 in the Journal of Clinical Oncology.
Steven J. Katz, M.D., M.P.H., from the University of Michigan Health Systems in Ann Arbor, and colleagues surveyed 5,080 patients aged 20 to 79 years diagnosed from July 2013 to August 2015 with early-stage breast cancer. Data were included for 1,711 patients with indications for formal genetic risk evaluation.
The researchers found that 47.4 percent of participants did not get tested, while 40.7, 7.4, and 4.5 percent tested negative, had a variant of uncertain significance, and had a pathogenic mutation, respectively. Overall, 74.6 percent received some form of genetic counseling (43.5 and 31.1 percent received formal counseling and physician-directed discussion, respectively). Almost all tested patients (96.1 percent) received some form of genetic discussion; only 50.6 percent of those not tested received any genetics discussion. Some form of counseling was more likely to be reported by younger women, with odds ratios of 4.5, 1.9, and 1.5, respectively, for women aged younger than 50 years, 50 to 59 years, and 60 to 69 years versus those aged ≥70 years, after adjustment for other factors.
"There is a large gap between mandates for timely pretest formal genetic counseling in higher-risk patients and the reality of practice today," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: March 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.